Tao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tao Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Cory Heilmann
Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA
1 shared publicationHaoda Fu
Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA
1 shared publicationJames Malone
Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA
1 shared publicationWilliam J. Huster
Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA
1 shared publicationYongming Qu
Eli Lilly and Company, Insulin and Device Development, Indianapolis, Indiana, USA
1 shared publication
Latest Publications
- Open Access
- 18 August 2016
- Published by Wiley in Journal of Diabetes
- Vol. 8 (5) , 610-618
Crossover design and its application in late‐phase diabetes studies
Crossover design has been widely used in late‐phase clinical studies, as well as in pharmacokinetic and pharmacodynamic, bioequivalence, and medical device studies; however, its interpretability and applicability continue to be debated. Herein we provide discussions around a crossover design's scientific benefit, applicability, and how it can be implemented in late‐phase diabetes studies by properly handling key issues: carryover effect, washout period, and baseline selection. Specifically, detailed considerations are provided about the validity and situations of having appropriate length of study duration to deal with carryover effects so that a washout period may not be needed. A simulation study and data mining results on 12 crossover late‐phase insulin clinical trials are presented to examine the discussion points and proposals.
- 18 August 2016
- Published by Wiley in Journal of Diabetes
- Vol. 8 (5) , 610-618
Open AccessCrossover design and its application in late‐phase diabetes studies
Crossover design has been widely used in late‐phase clinical studies, as well as in pharmacokinetic and pharmacodynamic, bioequivalence, and medical device studies; however, its interpretability and applicability continue to be debated. Herein we provide discussions around a crossover design's scientific benefit, applicability, and how it can be implemented in late‐phase diabetes studies by properly handling key issues: carryover effect, washout period, and baseline selection. Specifically, detailed considerations are provided about the validity and situations of having appropriate length of study duration to deal with carryover effects so that a washout period may not be needed. A simulation study and data mining results on 12 crossover late‐phase insulin clinical trials are presented to examine the discussion points and proposals.